Cancer vaccines include immunotherapeutics that treat cancer by administering cancer-specific antigens to stimulate the patient’s immune system.

Cancer vaccines can be classified into “preventative vaccines” and “therapeutic vaccines.” Although preventative vaccines have a large market share in the global cancer vaccine market, such market share is forecasted to decrease due to the emergence of therapeutic vaccines.

Therapeutic vaccines are immunotherapeutics that are less toxic compared to standard therapeutic modalities like radiation therapy and chemotherapy. By increasing the survival rate of cancer patients whose overall health is more tenuous, and thereby providing more treatment opportunities, therapeutic vaccines are expected to lead the growth of the cancer vaccine market.